Shattuck Labs Inc
STTK
Get informed when a big investor buys or sells
+ FollowMarket Cap$237.12M
Close$
$0.45
91.7% downside
Current Fair Value
91.7% downsideOvervalued by 91.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $237.12 Million |
|---|---|
| Enterprise Value | $148.74 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-0.7 |
| Beta | 1.09 |
| Outstanding Shares | 112,234,551 |
Return
| Return on Equity | -52.04% |
|---|---|
| Return on Assets | -48.84% |
| Return on Invested Capital | -53.73% |
Valuation & Multiples
| P/E Ratio | -11.14 |
|---|---|
| PEG | -143.32 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -2.83 |
| Enterprise Value to Net Income | -3 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.02 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
May 13, 2026
EPS Estimate
$-0.14
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
August 6, 2026
EPS Estimate
$-0.13
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 80.58%▲ 22.36% |
|---|---|
| Total Invested | $360.44M▲ 135.01% |
| Investors Holding | 83▲ 20.00% |
ESG Score
No data
About Shattuck Labs Inc
59 employeesShattuck Labs, Inc. operates as a clinical-stage biotechnology company . The Company focuses on developing a novel class of biologic medicines for the treatment of cancer and autoimmune diseases. Shattuck Labs serves customers in the State of Texas.